证券代码：000756 证券简称：新华制药 公告编号：2025-30 届时公司董事、总经理徐文辉先生，董事、财务负责人侯宁先生，董事会秘书曹 长求先生，证券事务代表田建华女士将在线就公司 2024 年度业绩、公司治理、发展战 略、经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流。如存在 特殊情况，公司将根据实际情况调整出席人员。欢迎广大投资者踊跃参与！ 特此公告！ 山东新华制药股份有限公司董事会 2025 年 5 月 12 日 山东新华制药股份有限公司 关于参加 2025 年山东辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山东新华制药股份有限公司（以下简称"公 司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联合举办 的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如 下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-29 山东新华制药股份有限公司 关于获得《药品补充申请批准通知书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监督管 理局核准签发的依帕司他片（以下简称"本品"）《药品补充申请批准通知书》，批准本品上市许可持 有人转让补充申请。现将相关情况公告如下： 一、基本情况 药品名称：依帕司他片 剂型：片剂 规格：50mg 药品分类：处方药 阶段支付相关转让费。 根据《深圳证券交易所股票上市规则》及《公司章程》等有关规定，本次交易事项无需提交公 司董事会及股东大会审议。本次交易事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 申请事项：上市许可持有人变更申请 受理号：CYHB2500728 原药品批准文号：国药准字H20253176 通知书编号：2025B01957 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事项符合 药品注册的有关要求，同意按 ...

Core Viewpoint - The company has made significant progress in product approvals and innovation, enhancing its market position and revenue potential in the pharmaceutical industry. Group 1: Product Approvals and Sales - In 2025, the company received multiple product approvals, including Mecobalamin tablets and enteric-coated Aspirin tablets, which will enrich its product line in the nervous system category [1] - The sales revenue for Mecobalamin tablets in Chinese public medical institutions was approximately 1.431 billion yuan in 2023, while the sales for enteric-coated Aspirin tablets reached about 3.3 billion yuan [1] Group 2: Research and Development - The company is focusing on R&D in various therapeutic areas, including cardiovascular, analgesics, digestive system, anti-metabolic, nervous system, and narcotic drugs, with over 100 drugs in the development pipeline [2][3] - It has established multiple large R&D platforms and is advancing several first-class innovative drugs, such as OAB-14 for Alzheimer's treatment [2] - The company emphasizes collaboration with academic institutions and has partnerships with over 50 domestic and international research organizations [3] Group 3: Financial Performance - In Q1 2025, the company reported a revenue of 2.43 billion yuan and a net profit of 112 million yuan [4] - For the year 2024, the total revenue was 8.466 billion yuan, reflecting a year-on-year growth of 4.51%, while the net profit was 470 million yuan, slightly declining due to price reductions aimed at market capture [4] - The company plans a high dividend distribution, proposing a payout of 2.5 yuan per 10 shares (including tax) for 2024 [4]

证券代码：000756 证券简称：新华制药 公告编号：2025-28 山东新华制药股份有限公司 关于获得《药品补充申请批准通知书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 剂型：片剂 规格：0.5mg 药品分类：处方药 申请人：山东新华制药股份有限公司 申请事项：上市许可持有人变更申请 受理号：CYHB2500726 原药品批准文号：国药准字H20234578 通知书编号：2025B01854 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事项符合药 品注册的有关要求，同意按照《药品上市后变更管理办法（试行）》相关规定，批准本品上市许可持有 人变更，药品批准文号不变。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的甲钴胺片（以下简称"本品"）《药品补充申请批准通知书》，批准本品上市许可持有人转 让补充申请。现将相关情况公告如下： 一、基本情况 药品名称：甲钴胺片 二、其他相关信息 新华制药与北京民康百草医药科技有限公司（以下简称"民康百草"）于2022年1 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-27 山东新华制药股份有限公司 关于阿司匹林肠溶片新增规格及通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 近日，山东新华制药股份有限公司（"新华制药"或"本公司"）收到国家药品监督管理局核准签 发的阿司匹林肠溶片（100mg）（"本品"）的《药品补充申请批准通知书》，本品通过仿制药质量和疗效 一致性评价（"仿制药一致性评价"）。现将相关情况公告如下： 一、基本情况 药品名称：阿司匹林肠溶片 剂型：片剂 规格：100mg 药品批准文号：国药准字H20258068 通知书编号：2025B01839 二、其他相关信息 2024年3月，新华制药向国家药品监督管理局药品审评中心（CDE）递交阿司匹林肠溶片增加规格 合并一致性评价注册申报资料并获受理，2025年4月获得《药品补充申请批准通知书》，审评结论为： 经审查，同意批准本品增加100mg规格的补充申请，核发药品批准文号，本品通过仿制药质量和疗效一 1 药品分类：处方药 注册分类：化学药品 申请人：山东新华制药股份有限公司 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-25 山东新华制药股份有限公司 三、审议通过关于召开 2024 年度周年股东大会的议案（股东大会通知将另行公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 备查文件 一、审议通过本公司 2025 年第一季度报告（见同日发布于《证券时报》及巨潮资讯网 （http://www.cninfo.com.cn）公告）； 9 名董事赞成本议案，0 票反对，0 票弃权。 二 、 审 议 通 过 了 2024 年 环 境 、 社 会 及 管 治 报 告 （ 见 同 日 发 布 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 第十一届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会第七次会议通知于二零二五年四 月十四日以电邮方式发出，会议于二零二五年四月二十八日在山东省淄博市高新区鲁泰大道 1 号公司会议室召开，应到会董事 9 名，实际参会董事 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,429,825,335.81, a decrease of 1.81% compared to ¥2,474,697,457.66 in the same period last year[5] - Net profit attributable to shareholders was ¥112,095,257.24, down 20.99% from ¥141,879,437.62 year-on-year[5] - Basic and diluted earnings per share were both ¥0.15, representing a decline of 28.57% from ¥0.21 in the same period last year[5] - Total comprehensive income for the current period was 104,998,682.16, down from 146,079,426.17 in the previous period, a decrease of about 28.2%[20] - Net profit for the current period was 115,643,803.12, down from 145,264,098.40 in the previous period, representing a decrease of approximately 20.4%[19] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 77.87%, amounting to ¥8,425,190.10 compared to ¥38,063,364.43 in the previous year[5] - Cash flow from operating activities generated a net amount of 8,425,190.10, significantly lower than 38,063,364.43 in the previous period[21] - The decline in net cash flow from operating activities was attributed to an increase in the proportion of bank acceptance bill collections and a decrease in inventory changes compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,269,855,861.11, an increase of 2.77% from ¥9,019,601,567.53 at the end of the previous year[5] - The total current assets increased to ¥3,999,396,150.59 from ¥3,726,840,162.91, reflecting a growth of about 7.3%[16] - Accounts receivable rose significantly to ¥1,200,307,190.06, up from ¥868,204,001.79, indicating an increase of approximately 38.2%[16] - The total liabilities increased to ¥3,879,907,761.23 from ¥3,802,101,150.19, marking a rise of about 2.0%[17] - The non-current liabilities decreased to ¥645,097,935.77 from ¥1,006,487,037.80, a reduction of approximately 35.9%[17] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.28% to ¥5,155,519,978.65 from ¥4,991,588,524.78[5] - The total equity attributable to shareholders increased to ¥5,155,519,978.65 from ¥4,991,588,524.78, indicating a growth of approximately 3.3%[17] Expenses - Research and development expenses for the current period were 109,788,595.18, compared to 141,905,763.44 in the previous period, showing a reduction of approximately 22.6%[19] - The company reported a decrease in sales expenses from 291,064,033.27 in the previous period to 99,952,491.15 in the current period, a reduction of about 65.6%[19] - The company's total operating costs decreased from 2,328,929,009.30 to 2,299,988,387.70, a reduction of approximately 1.2%[19] Other Income and Changes - The company reported non-operating income of ¥7,067,182.83, primarily from government subsidies and asset disposal gains[7] - The company approved changes to accounting policies that are not expected to have a significant impact on the financial statements[13] - The company experienced an investment loss of 760,243.82 in the current period, compared to a gain of 1,188,728.16 in the previous period[19]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplementary application of Mecobalamin tablets, allowing the transfer of the marketing authorization holder [1] Company Summary - The transaction does not require approval from the company's board of directors or shareholders, as it does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - Mecobalamin tablets are indicated for peripheral neuropathy and are listed as a Class B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Industry Summary - In 2023, the sales revenue of Mecobalamin tablets in Chinese public medical institutions is approximately RMB 1.431 billion [1]

Group 1: Company Growth and Innovation Strategies - The company is focusing on establishing innovation platforms with renowned research institutions to enhance high-value new drug development and accelerate results transformation [2][3] - There are over 100 drugs in the research pipeline, including multiple first-class innovative drugs like OAB-14 for Alzheimer's treatment [3][4] - The company aims to deepen internationalization and strengthen its position in the high-value raw material drug market [2][3] Group 2: Financial Performance and Market Position - In 2024, the company achieved a revenue of 8.466 billion yuan, representing a year-on-year growth of 4.51% [6][9] - The company emphasizes cash dividends, with the cash dividend ratio significantly exceeding the stipulated proportion in its articles of association [2][3] - The company's price-to-earnings ratio is lower than most pharmaceutical companies, raising concerns about potential stock buybacks [2][6] Group 3: Cost Control and Efficiency Measures - The company implements comprehensive budget management to control expenses and enhance operational efficiency [3][4] - Measures include optimizing procurement processes and production operations to reduce costs while maintaining quality [3][4] Group 4: Market Challenges and Stock Performance - Despite the approval of multiple new products, the stock price has been declining, influenced by market competition, industry policies, and investor sentiment [5][9] - The company acknowledges the impact of macroeconomic uncertainties and competitive pressures on its market value [9][10] Group 5: Investor Relations and Communication - The company is committed to enhancing communication with investors through regular reports and performance briefings [6][9] - The recent investor relations activities aim to rebuild investor confidence and clarify the company's strategic direction [6][9] Group 6: Industry Outlook - The pharmaceutical industry is expected to grow due to increasing health awareness and an aging population, with innovation driving new drug development [11]